[{"id":"42d2a0f4-bf25-41be-9b41-ecad4c959f5d","acronym":"CK-301-101","url":"https://clinicaltrials.gov/study/NCT03212404","created_at":"2021-01-18T15:50:41.447Z","updated_at":"2025-02-25T16:59:32.024Z","phase":"Phase 1","brief_title":"Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers","source_id_and_acronym":"NCT03212404 - CK-301-101","lead_sponsor":"Checkpoint Therapeutics, Inc.","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Unloxcyt (cosibelimab-ipdl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 272","initiation":"Initiation: 09/20/2017","start_date":" 09/20/2017","primary_txt":" Primary completion: 11/18/2021","primary_completion_date":" 11/18/2021","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-03"}]